spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  rosuvastatin 

 HSMN NewsFeed - 11 Oct 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2018
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 16 Nov 2016
Marina Biotech Announces Merger with IthenaPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Jul 2016
Mylan Launches Generic Crestor(R) Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 2 May 2016
Allergan Receives FDA Approval and Launches First Generic Version of CRESTOR(R) (rosuvastatin)
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 14 Jun 2012
EMD Serono, Inc. Strengthens Leadership Teams with New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2010
Abbott and AstraZeneca End License Agreement for the Development of CERTRIAD
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 27 Apr 2010
CRESTOR(TM) Gains New EU Indication to Prevent Major Cardiovascular Events in High Risk Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Mar 2010
AstraZeneca and Abbott Receive FDA Complete Response Letter on CERTRIAD(TM) New Drug Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 8 Jun 2009
Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2009
New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2009
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Dec 2008
Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 31 May 2008
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 May 2008
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
Devices Interventional
 HSMN NewsFeed - 31 Mar 2008
Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
First Head to Head Study Comparing Crestor(TM) and Lipitor(R) Effects on the Treatment of Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Nov 2007
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 9 Nov 2007
CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 7 Nov 2007
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Aug 2007
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2007
First Study to Show Positive Benefit on Atherosclerosis for People With Early Signs of Diseased Arteries
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Jan 2007
Statins Can Slow Progression of Aortic Valve Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Oct 2006
FDA Approves New Label for VYTORIN(R) (ezetimibe/simvastatin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Sep 2006
New EXPLORER Results Show Patients Achieved Dramatic Reductions in C-Reactive Protein And LDL-C Levels With CRESTOR Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Jul 2006
Abbott and AstraZeneca Announce Collaboration to Develop and Commercialize CRESTOR(R) and Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
CRESTOR Helped More Patients Reach Goal in MERCURY II Study
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
rosuvastatin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.